Immunotherapy of melanoma preferably consists of the PD-1 blockers nivolumab and pembrolizumab and the CTLA-4 antibody ipilimumab as monotherapies or in combination, the latter of which has advantages for patients with metastatic melanoma. This evidence concerns the gene CTLA4 and metastatic melanoma.